ArticleNature chemical biology2011
Drug discovery: New Btk inhibitor holds promise.
Article in Nature chemical biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.The Lancet. Neurology · 2021Trial
- Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.Clinical and translational science · 2020Trial
- Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.Science (New York, N.Y.) · 2024Article
- c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights.OncoTargets and therapy · 2023Review
- Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial.ACR open rheumatology · 2023Article
- Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus.Journal of clinical medicine · 2022Review
- Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.Clinical and translational science · 2021Article
- Inflammasome activation controlled by the interplay between post-translational modifications: emerging drug target opportunities.Cell communication and signaling : CCS · 2021Review
- Bruton's Tyrosine Kinase Inhibition Promotes Myelin Repair.Brain plasticity (Amsterdam, Netherlands) · 2020Article
- KIT and Melanoma: Biological Insights and Clinical Implications.Yonsei medical journal · 2020Review
- Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor.International journal of molecular sciences · 2020Article
- Neuropsychiatric lupus: new mechanistic insights and future treatment directions.Nature reviews. Rheumatology · 2019Review
- Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.Arthritis research & therapy · 2018Article
- Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature.Oncotarget · 2017Article
- Nonreceptor tyrosine kinases ITK and BTK negatively regulate mast cell proinflammatory responses to lipopolysaccharide.The Journal of allergy and clinical immunology · 2016Article
- Bruton tyrosine kinase (Btk) suppresses osteoblastic differentiation.Journal of bone and mineral metabolism · 2015Article
- Review
- New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.Nature reviews. Immunology · 2013Review
- SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.Cancer cell · 2013Article
- The C-kit receptor-mediated signal transduction and tumor-related diseases.International journal of biological sciences · 2013Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
21164510What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.